OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

To reveal more filter options, please select whether you would like to review Active or Closed projects:

Clear

814 Projects | 562 Researchers | $391,054,388 Invested

2026

MindImmune Therapeutics, Inc.

Frank Menniti, PhD

MITI-101, a novel antibody therapeutic to treat Alzheimer's disease and related disorders

  • Funding Amount: $5,014,485
  • Organization Type:
  • Program: Clinical
  • Target: Inflammation
  • Status: Active

2025

Superfluid Dx

Bojk Berghuis

Integrating cfRNA and Proteomics with AI for Next-Generation Alzheimer’s Diagnostics

  • Funding Amount: $911,250
  • Organization Type:
  • Program: Diagnostics Accelerator
  • Target: Other
  • Status: Active

2025

Alzheimers Disease Data Initiative (ADDI)

Farhad Imam

The Global Neurodegeneration Proteomics Consortium: V2 expansion for ADNI and other key AD datasets

  • Funding Amount: $1,881,800
  • Organization Type:
  • Program: Diagnostics Accelerator
  • Target: Other
  • Status: Active

2025

Board of Trustees of the Leland Stanford Junior University

Michelle James, PhD

Development of new PET radiotracers for detecting and tracking innate immune activation in the whole body and CNS of Alzheimer's disease

  • Funding Amount: $350,385
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Status: Active

2025

The University of Edinburgh

Neil McKenzie, PhD, CChem, MSc, BSc(Hons)

“The development and evaluation of a clinical RT-QuIC test for diagnosis of TDP-43 linked Fronto-temporal dementias: A small multicentre trial.”

  • Funding Amount: $144,585
  • Organization Type:
  • Program: Biomarkers
  • Status: Active

2025

Emtherapro

Nicholas Seyfried

A novel, accurate plasma proteomic assay for screening and diagnosis of individuals with Alzheimer’s Disease and Alzheimer’s Disease Related Dementia (AD/ADRD)

  • Funding Amount: $499,415
  • Organization Type:
  • Program: Diagnostics Accelerator
  • Status: Active

2025

Icahn School of Medicine at Mount Sinai

Alison Goate, D.Phil.

Development of a Scalable CSF YWHAG:NPTX2 ELISA Assay for Cognitive Prognosis in Early AD

  • Funding Amount: $598,982
  • Organization Type:
  • Program: Biomarkers
  • Status: Active

2025

Vesper Bio ApS

Mads Fuglsang Kjølby

Open-label multiple dosing study in asymptomatic GRN-Frontotemporal dementia patients to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VES001.

  • Funding Amount: $2,549,203
  • Organization Type:
  • Program: Clinical
  • Status: Active

2025

The University of Texas Southwestern Medical Center at Dallas

Marc Diamond, MD

AAV-mediated clearance of tau aggregates in vivo

  • Funding Amount: $600,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Active

2025

University of Illinois at Chicago

Steven Ackerman, PhD

Development of novel CCR3 chemokine receptor peptide and small molecule functionally selective biased antagonists to treat neuroinflammation in Alzheimer’s disease.

  • Funding Amount: $599,515
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Active
View More